MPs debate Spinraza access and changes to NICE appraisal processes

Following a few discussions and meetings between TreatSMA and MPs over the last few weeks today has seen the MPs debated the failure to provide Spinraza to all families who needed access.

Mary Glidon MP in an earlier debate used part of her speech to mention the debate and those needing access to Spinraza.

Then Sir John Hayes MP gave a moving case for the upset felt by families who originally thought they would get access but are now excluded (see above). We wanted to thank all families for contacting their MPs regarding this debate. As a small charity we need others to help to make access successful. You have all shown this by making this debate possible.

The TreatSMA community made this happen, you should be very proud.

TreatSMA Team

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more